Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

Background AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor (FGFR) inhibitor in clinical development for treating tumours with a range of FGFR aberrations, including FGFR mutations, amplifications and fusions. Methods This open-label, Phase I, multicentre study (NCT01213...

Descripción completa

Detalles Bibliográficos
Autores principales: Saka, Hideo, Kitagawa, Chiyoe, Kogure, Yoshihito, Takahashi, Yasuo, Fujikawa, Koshi, Sagawa, Tamotsu, Iwasa, Satoru, Takahashi, Naoki, Fukao, Taro, Tchinou, Catherine, Landers, Dónal, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502072/
https://www.ncbi.nlm.nih.gov/pubmed/28070720
http://dx.doi.org/10.1007/s10637-016-0416-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502072/
https://www.ncbi.nlm.nih.gov/pubmed/28070720
http://dx.doi.org/10.1007/s10637-016-0416-x

Ejemplares similares